Original Article | Published:

Clinical Studies and Practice

Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events

International Journal of Obesity volume 39, pages 156161 (2015) | Download Citation

Abstract

Introduction:

Irisin is a newly discovered myokine, associated with 'browning' of the white adipose tissue, obesity, insulin resistance and metabolic syndrome. The purpose of this study is to evaluate circulating irisin as a predictor of acute coronary syndromes (ACSs) and major adverse cardiovascular events (MACE).

Methods:

Sub-study 1: a case–control study, nested within the Veteran’s Affairs Normative Ageing Study, evaluating circulating irisin levels in 88 ACS cases and 158 age- and sampling year-matched controls, as a predictor of ACS. Sub-study 2: a prospective cohort study, where 103 participants with established coronary artery disease were stratified by circulating irisin levels at the time they received percutaneous coronary interventions (PCIs) and were followed for the development of MACE.

Results:

Study 1: there was no association between irisin levels and ACS in otherwise healthy individuals (odds ratio: 1.00 95% confidence interval: (0.99–1.00)). Study 2: the incidence of MACE was significantly lower in the first irisin tertile compared with the second and third (incidence rate 0 vs 0.92 (0.51–1.61) vs 0.57 (0.28–1.14) events per 1000 person-days; P<0.01). This was primarily driven by the lower incidence of unstable angina (incidence rate 0 vs 0.61 (0.31–1.22) vs 0.43 (0.19–0.96) per 1000 person-days; P=0.01).

Conclusion:

This is the first study to date that demonstrates that, although circulating irisin levels do not predict the development of ACS in healthy individuals, increased irisin levels are associated with the development of MACE in patients with established coronary artery disease after PCI.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    . A muscular twist on the fate of fat. N Engl J Med 2012; 366: 1544–1545.

  2. 2.

    , , , , , et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463–468.

  3. 3.

    , , . Developmental origin of fat: tracking obesity to its source. Cell 2007; 131: 242–256.

  4. 4.

    , , , , , et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J Clin Invest 2013; 123: 215–223.

  5. 5.

    , , . Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance. Obes Res 2003; 11: 1182–1191.

  6. 6.

    , , , , , . Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index. Peptides 2013; 39: 125–130.

  7. 7.

    , , , , , et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899–4907.

  8. 8.

    , , , , , et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 365–369.

  9. 9.

    , , , . Irisin: a renaissance in metabolism? Metabolism 2013; 62: 1037–1044.

  10. 10.

    , , , , , et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev 2013; 34: 377–412.

  11. 11.

    , , , , , . Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.

  12. 12.

    , . Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther 2012; 10: 933–939.

  13. 13.

    , , . Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341–1350.

  14. 14.

    , , , . Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190–1200.

  15. 15.

    , , , , , et al. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ Heart Fail 2012; 5: 812–818.

  16. 16.

    , , . The Veterans Administration longitudinal study of healthy aging. Gerontologist 1966; 6: 179–184.

  17. 17.

    , , . Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 1991; 65: 105–114.

  18. 18.

    , , , , , et al. Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention. Eur Heart J 2009; 30: 2614–2621.

  19. 19.

    , , , , , et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634–2653.

  20. 20.

    , , , , , et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725–1738.

  21. 21.

    , , , , . Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2013; 163: 207–217.

  22. 22.

    , , , , , et al. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men. Obes Res 1998; 6: 179–186.

  23. 23.

    , , , , . Independent circadian and sleep/wake regulation of adipokines and glucose in humans. J Clin Endocrinol Metab 2005; 90: 2537–2544.

  24. 24.

    , , . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

  25. 25.

    , , , . Is irisin a human exercise gene? Nature 2012; 488: E9–10 (Discussion E10-1).

  26. 26.

    , , . Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass. Metabolism 2013; 62: 1070–1073.

  27. 27.

    , , , , , et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769–E778.

  28. 28.

    , , , , , et al. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism 2013; 62: 1052–1056.

  29. 29.

    , , , , , et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 2013; 100: 96–101.

  30. 30.

    , , , , , et al. Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans. Eur J Endocrinol 2013; 169: 829–834.

  31. 31.

    , , . Irisin in humans: recent advances and questions for future research. Metabolism 2014; 63: 178–180.

  32. 32.

    , , , , , et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One 2013; 8: e72858.

  33. 33.

    , , , , , et al. Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs. Metabolism 2013; 62: 1503–1511.

Download references

Acknowledgements

The Mantzoros Laboratory is supported by Award Number 1I01CX000422–01A1 from the Clinical Science Research and Development Service of the VA Office of Research and Development. NAS is supported by Cooperative Studies Program/ERIC, US Department of Veterans Affairs and is a research component of the Massachusetts Veterans Epidemiology Research and Information Center. Dr Spiro is supported by a Research Career Scientist award from the Clinical Science Research and development service, US department of veterans’ affairs. This study was also supported by the Spanish Ministry of Health (FIS 2011-00214) and CIBERobn Fisiopatología de la Obesidad y la Nutrición (CIBERobn). The CIBER de la Fisiopatología de la Obesidad y Nutrición (CIBERobn) is an initiative from the Instituto de Salud Carlos III (ISCIII).

Author Contributions

All authors have read and agree with the content of the manuscript. KNA wrote the manuscript, collected data and performed the statistical analysis. MM contributed in the prospective study of this project, wrote the manuscript and collected data. SAP wrote the manuscript and contributed to the statistical analysis. JMM-N, WR, ED, JdlH contributed in the prospective study of this project. AS-E, ASIII, PV coordinated the Normative Ageing Study. JPC and RB performed the assays. JM-F-R and CSM supervised the study

Author information

Author notes

    • K N Aronis
    •  & M Moreno

    These authors share equal first co-authorship.

Affiliations

  1. Section of Endocrinology, Department of Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA

    • K N Aronis
    • , A Sahin-Efe
    • , J P Chamberland
    • , R Berman
    •  & C S Mantzoros
  2. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    • K N Aronis
    • , A Sahin-Efe
    • , J P Chamberland
    • , R Berman
    •  & C S Mantzoros
  3. Department of Medicine, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA

    • K N Aronis
  4. Department of Diabetes, Endocrinology and Nutrition, Institut d’Investigació Biomèdica de Girona (IdIBGi), CIBEROBN (CB06/03/010) and Instituto de Salud Carlos III (ISCIII), Girona, Spain

    • M Moreno
    • , J M Moreno-Navarrete
    •  & W Ricart
  5. Second Medical Clinic, Aristotle University of Thessaloniki, Ippokration General Hospital, Thessaloniki, Greece

    • S A Polyzos
  6. Central Hospital of Asturias, Oviedo, Spain

    • E Delgado
    • , J de la Hera
    •  & J M Fernández-Real
  7. Normative Aging Study, VA Boston Healthcare System and Boston University Schools of Public Health and Medicine, Boston, MA, USA

    • A Spiro III
  8. Normative Aging Study, VA Boston Healthcare System and Boston University School of Medicine, Boston, MA, USA

    • P Vokonas

Authors

  1. Search for K N Aronis in:

  2. Search for M Moreno in:

  3. Search for S A Polyzos in:

  4. Search for J M Moreno-Navarrete in:

  5. Search for W Ricart in:

  6. Search for E Delgado in:

  7. Search for J de la Hera in:

  8. Search for A Sahin-Efe in:

  9. Search for J P Chamberland in:

  10. Search for R Berman in:

  11. Search for A Spiro III in:

  12. Search for P Vokonas in:

  13. Search for J M Fernández-Real in:

  14. Search for C S Mantzoros in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to J M Fernández-Real.

Supplementary information

Word documents

  1. 1.

    Supplementary Tables

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/ijo.2014.101

Supplementary Information accompanies this paper on International Journal of Obesity website (http://www.nature.com/ijo)

Further reading